Patent Assignment
Reel/Frame 030062/0381
Change of Name
Recorded: 2013-03-21
Received: 2013-03-21
Pages: 28
Assignor
NYCOMED GMBH
Executed: 2012-11-14
Assignee
TAKEDA GMBH
BYK-GULDEN-STRASSE 2, KONSTANZ, DEX, 78467, GERMANY
Covered Properties
(21)
Oral Administration Form for Pyridin-2-Ylmethylsulfinyl-1H Benzimidazoles
Application:
12/153,585 →
Novel Preparation and Administration Form Comprising an Acid-Labile Active Compound
Application:
11/980,572 →
Tetrahydropyridoethers
Application:
11/493,707 →
Oral Administration Form for Pyridin-2-Ylmethylsulfinyl-1H-Benzimidazoles
Application:
11/377,404 →
Novel Preparation and Administration Form Comprising an Acid-Labile Active Compound
Application:
11/349,969 →
Surfactant Protein C Esters
Application:
11/287,197 →
Tetrahydropyridoethers
Application:
10/783,512 →
Synergistic Combination
Application:
10/437,005 →
Novel Administration Form Comprising an Acid-Labile Active Compound
Application:
10/423,002 →
Synergistic Combination Comprising Roflumilast and a Pde-3 Inhibitor
Application:
10/286,915 →
Novel Salt Form of Pantoprazole
Application:
10/135,528 →
Synergistic Combination
Application:
10/049,999 →
Synergistic Combination Comprising Roflumilast and a Pde-3 Inhibitor
Application:
09/959,599 →
Novel Preparation and Administration Form Comprising an Acid-Labile Active Compound
Application:
09/980,492 →
Surfactant Protein C Esters
Application:
09/959,628 →
Administration Form Comprising an Acid-Labile Active Compound
Application:
09/983,990 →
3-Cyclopropylmethoxy-4-Difluoromethoxy-N-(3,5-Dichloropyrid-4-Yl)Benzamide in the Treatment of Multiple Sclerosis
Application:
09/914,763 →
Phenylphennanthridines with Pde-Iv Inhibiting Activity
Application:
09/889,144 →
Determination of the Hydrophobic Pulmonary Surfactant Protein Sp-C
Application:
09/720,830 →
Oral Administration Form for Pyridin-2-Ylmethylsulfinyl-1H-Benzimidazoles
Application:
09/762,302 →
Novel Salt Form of Pantoprazole
Application:
09/762,303 →